On Friday, the country's health service stated that patients with Lung cancer in England will become the first in Europe to receive a drug made by U.S. biotech Amgen Inc (AMGN.O) which targets a specific gene mutation, According to NHS England, it was fast-tracking lung cancer drug sotorasib